Friedländer, M nolva tamoxifen Similarly, the American Society of Clinical Oncology ASCO technology assessment on the use of aromatase inhibitors as adjuvant therapy also states that these agents should be considered for use in postmenopausal women with hormone receptor positive breast cancer
Recent Comments